Axsome Therapeutics (AXSM) to Release Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM) will likely be posting its quarterly earnings results before the market opens on Tuesday, February 18th. Analysts expect Axsome Therapeutics to post earnings of ($0.97) per share and revenue of $118.42 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. During the same quarter in the previous year, the company earned ($1.32) EPS. On average, analysts expect Axsome Therapeutics to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Axsome Therapeutics Stock Up 20.2 %

NASDAQ AXSM opened at $127.08 on Tuesday. The company has a market cap of $6.16 billion, a price-to-earnings ratio of -19.46 and a beta of 1.05. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $132.25. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The company has a 50 day moving average of $94.72 and a 200-day moving average of $91.78.

Analyst Ratings Changes

AXSM has been the topic of several analyst reports. Robert W. Baird increased their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Royal Bank of Canada restated an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a research report on Wednesday, January 29th. HC Wainwright increased their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Cantor Fitzgerald restated an “overweight” rating and set a $121.00 target price on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Finally, William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $135.14.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.